• Something wrong with this record ?

Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C

MC. Patterson, U. Ramaswami, A. Donald, T. Foltan, M. Gautschi, P. Gissen, A. Hahn, SA. Jones, R. Kay, M. Kolniková, J. Park, S. Reichmannová, M. Walterfang, P. Wibawa, M. Rohrbach, K. Martakis, T. Bremova-Ertl

. 2025 ; 105 (1) : e213589. [pub] 20250613

Language English Country United States

Document type Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc25015167

BACKGROUND AND OBJECTIVES: N-acetyl-l-leucine (NALL) has been established to improve the neurologic manifestations of Niemann-Pick disease type C (NPC) after 12 weeks in a placebo-controlled trial. In the open-label extension phase (EP) follow-up, data were obtained after 12 and 18 months to evaluate the long-term effects of NALL for NPC. METHODS: This is an ongoing, multinational, multicenter EP. Patients with a genetic diagnosis of NPC aged 4 years or older who completed the placebo-controlled trial were eligible to continue in the EP and receive orally administered NALL 2-3 times per day in 3 tiers of weight-based dosing. The primary end point is the modified 5-domain NPC Clinical Severity Scale (NPC-CSS) (range 0-25 points; lower score representing better neurologic status); data from the EP cohort are compared with the expected annual trajectory of decline (i.e., disease progression) established in natural history studies. Analyses are also performed on exploratory end points, including the 15-domain and 4-domain NPC-CSSs and the Scale for Assessment and Rating of Ataxia (SARA). RESULTS: Fifty-three patients aged 5-67 years (45.3% female, 54.7% male) were enrolled in the EP. After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was -0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI -3.05 to -0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression. After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI -4.06 to -0.35; p = 0.023). The 15-domain and 4-domain NPC-CSSs were consistent with the 5-domain NPC-CSS. The improvements in neurologic manifestations demonstrated in the placebo-controlled trial on the primary SARA end point were sustained over the long-term follow-up. NALL was well tolerated, and no treatment-related adverse events or serious reactions occurred. DISCUSSION: Treatment with NALL was associated with a significant reduction in NPC disease progression after 12 and 18 months, demonstrating a disease-modifying, neuroprotective effect. TRIAL REGISTRATION INFORMATION: The trial is registered with ClinicalTrials.gov (NCT05163288; registered December 6, 2021), EudraCT (2021-005356-10). The first patient was enrolled into the EP on March 8, 2023. The trial was funded by IntraBio Inc. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that NALL reduces disease progression in NPC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015167
003      
CZ-PrNML
005      
20250731090808.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1212/WNL.0000000000213589 $2 doi
035    __
$a (PubMed)40513057
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Patterson, Marc C $u Departments of Neurology, Pediatrics and Clinical Genomics, Mayo Clinic Children's Center, Rochester, MN
245    10
$a Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C / $c MC. Patterson, U. Ramaswami, A. Donald, T. Foltan, M. Gautschi, P. Gissen, A. Hahn, SA. Jones, R. Kay, M. Kolniková, J. Park, S. Reichmannová, M. Walterfang, P. Wibawa, M. Rohrbach, K. Martakis, T. Bremova-Ertl
520    9_
$a BACKGROUND AND OBJECTIVES: N-acetyl-l-leucine (NALL) has been established to improve the neurologic manifestations of Niemann-Pick disease type C (NPC) after 12 weeks in a placebo-controlled trial. In the open-label extension phase (EP) follow-up, data were obtained after 12 and 18 months to evaluate the long-term effects of NALL for NPC. METHODS: This is an ongoing, multinational, multicenter EP. Patients with a genetic diagnosis of NPC aged 4 years or older who completed the placebo-controlled trial were eligible to continue in the EP and receive orally administered NALL 2-3 times per day in 3 tiers of weight-based dosing. The primary end point is the modified 5-domain NPC Clinical Severity Scale (NPC-CSS) (range 0-25 points; lower score representing better neurologic status); data from the EP cohort are compared with the expected annual trajectory of decline (i.e., disease progression) established in natural history studies. Analyses are also performed on exploratory end points, including the 15-domain and 4-domain NPC-CSSs and the Scale for Assessment and Rating of Ataxia (SARA). RESULTS: Fifty-three patients aged 5-67 years (45.3% female, 54.7% male) were enrolled in the EP. After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was -0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI -3.05 to -0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression. After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI -4.06 to -0.35; p = 0.023). The 15-domain and 4-domain NPC-CSSs were consistent with the 5-domain NPC-CSS. The improvements in neurologic manifestations demonstrated in the placebo-controlled trial on the primary SARA end point were sustained over the long-term follow-up. NALL was well tolerated, and no treatment-related adverse events or serious reactions occurred. DISCUSSION: Treatment with NALL was associated with a significant reduction in NPC disease progression after 12 and 18 months, demonstrating a disease-modifying, neuroprotective effect. TRIAL REGISTRATION INFORMATION: The trial is registered with ClinicalTrials.gov (NCT05163288; registered December 6, 2021), EudraCT (2021-005356-10). The first patient was enrolled into the EP on March 8, 2023. The trial was funded by IntraBio Inc. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that NALL reduces disease progression in NPC.
650    _2
$a lidé $7 D006801
650    12
$a Niemannova-Pickova nemoc typu C $x farmakoterapie $7 D052556
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    _2
$a předškolní dítě $7 D002675
650    _2
$a mladiství $7 D000293
650    _2
$a mladý dospělý $7 D055815
650    12
$a leucin $x analogy a deriváty $x terapeutické užití $7 D007930
650    12
$a neuroprotektivní látky $x terapeutické užití $7 D018696
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a progrese nemoci $7 D018450
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a následné studie $7 D005500
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Ramaswami, Uma $u Lysosomal Storage Disorder Unit, Royal Free London NHS Foundation Trust, United Kingdom
700    1_
$a Donald, Aimee $u Willink Unit, Manchester Centre for Genomic Medicine, Royal Manchester Children's Hospital, University of Manchester, United Kingdom
700    1_
$a Foltan, Tomas $u Department of Pediatric Neurology, National Institute of Children's Diseases, Comenius University in Bratislava, Slovak Republic
700    1_
$a Gautschi, Matthias $u Department of Neurology, University Hospital Bern (Inselspital), Switzerland
700    1_
$a Gissen, Paul $u NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, United Kingdom $1 https://orcid.org/0000000297126122
700    1_
$a Hahn, Andreas $u Department of Child Neurology, Justus Liebig University, Giessen, Germany $1 https://orcid.org/0000000302355211
700    1_
$a Jones, Simon A $u Willink Unit, Manchester Centre for Genomic Medicine, Royal Manchester Children's Hospital, University of Manchester, United Kingdom $1 https://orcid.org/0000000251170566
700    1_
$a Kay, Richard $u RK Statistics, Brook House, Mesne Lane, Bakewell, United Kingdom
700    1_
$a Kolniková, Miriam $u Department of Pediatric Neurology, National Institute of Children's Diseases, Comenius University in Bratislava, Slovak Republic $1 https://orcid.org/0009000259609972
700    1_
$a Park, Julien $u Department of General Paediatrics, University of Münster, Germany
700    1_
$a Reichmannová, Stella $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Walterfang, Mark $u Department of Neuropsychiatry, The Royal Melbourne Hospital, Melbourne, Australia $1 https://orcid.org/0000000213893691
700    1_
$a Wibawa, Pierre $u Department of Neuropsychiatry, The Royal Melbourne Hospital, Melbourne, Australia
700    1_
$a Rohrbach, Marianne $u Division of Metabolism and Children's Research Centre, University Children's Hospital Zurich, Switzerland; and
700    1_
$a Martakis, Kyriakos $u Department of Child Neurology, Justus Liebig University, Giessen, Germany $u Department of Pediatrics, Medical Faculty and University Hospital, University of Cologne, Germany $1 https://orcid.org/0000000339820914
700    1_
$a Bremova-Ertl, Tatiana $u Department of Neurology, University Hospital Bern (Inselspital), Switzerland $1 https://orcid.org/000000027397045X
773    0_
$w MED00003491 $t Neurology $x 1526-632X $g Roč. 105, č. 1 (2025), s. e213589
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40513057 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090802 $b ABA008
999    __
$a ok $b bmc $g 2366178 $s 1252292
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 105 $c 1 $d e213589 $e 20250613 $i 1526-632X $m Neurology $n Neurology $x MED00003491
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options